Do you offer surveillance brain imaging for patients with EGFR+ NSCLC, stable systemic disease on TKI, and no history of metastatic brain disease?

There are very few data based on randomized trials but we know that the brain is a major site of progression even with osimertinib so I get a brain MRI every 6 months.

In the absence of data showing improved clinical outcomes from surveillance, and in light of the anxiety and costs associated with scans, I don’t.